PPARA and metabolic dysfunction-associated steatohepatitis: Furthermore, treatment with PPAR agonists has been shown to prevent HCC in animal models by reducing NASH progression; saroglitazar (3 mg/kg/day, p.o.)completely prevented hepatic tumorigenesis [69] and pioglitazone inhibited the progression of hepatic steatosis and fibrosis, and reduced preneoplastic lesions [70].